Johnson & Johnson remains one of the most dependable names in healthcare investing. Following its Kenvue consumer health spinoff, JNJ is now a focused pharmaceutical and MedTech company, better positioned to capitalize on aging demographics through oncology, immunology, and surgical innovations.

The stock has surged nearly 57% over the past year, now trading near its 52-week high of $246.35 and well above its 50-day moving average. This rally has stretched the P/E ratio to 32.37"elevated relative to historical norms"raising valuation concerns for new entrants. EPS of $7.52 reflects solid but not exceptional earnings power.

As a Dividend Aristocrat with 60+ consecutive years of increases, JNJ's income reliability is unmatched, though the current yield has compressed due to price appreciation. The pharmaceutical pipeline, including Darzalex and Tremfya, provides meaningful growth catalysts, while MedTech benefits from procedure volume recovery.

Key risks include ongoing talc litigation liabilities, patent cliffs on major drugs, and the premium valuation. The bull case centers on pipeline execution, demographic tailwinds, and defensive positioning during economic uncertainty. A strong core holding, though dollar-cost averaging may be prudent at current levels.

Johnson & Johnson remains a definitive blue-chip holding, recently demonstrating robust momentum as it trades near its 52-week high of $240.94. Following its strategic restructuring to focus on high-growth pharmaceutical and MedTech segments, the stock has surged well above its 50-day moving average. However, the current valuation warrants caution; at a P/E ratio of 31.70, JNJ is trading at a significant premium to its historical range, suggesting that optimistic growth expectations are already priced in. While the company's legendary status as a Dividend King continues to attract income investors seeking stability, the stretched multiple may limit near-term upside. JNJ represents a high-quality defensive play with a fortress balance sheet, but value-conscious investors might prefer to wait for a pullback before adding to positions.